Attached files
| file | filename |
|---|---|
| 10-K - 10-K - Global Blood Therapeutics, Inc. | d843865d10k.htm |
| EX-32.2 - EX-32.2 - Global Blood Therapeutics, Inc. | d843865dex322.htm |
| EX-32.1 - EX-32.1 - Global Blood Therapeutics, Inc. | d843865dex321.htm |
| EX-31.2 - EX-31.2 - Global Blood Therapeutics, Inc. | d843865dex312.htm |
| EX-31.1 - EX-31.1 - Global Blood Therapeutics, Inc. | d843865dex311.htm |
| EX-21.1 - EX-21.1 - Global Blood Therapeutics, Inc. | d843865dex211.htm |
| EX-10.21 - EX-10.21 - Global Blood Therapeutics, Inc. | d843865dex1021.htm |
| EX-10.20 - EX-10.20 - Global Blood Therapeutics, Inc. | d843865dex1020.htm |
| EX-4.2 - EX-4.2 - Global Blood Therapeutics, Inc. | d843865dex42.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
Global Blood Therapeutics, Inc.:
We consent to the incorporation by reference in the registration statements (Nos. 333-206329, 333-210475, 333-215732, 333-222803, 333-226051, 333-229392, 333-232427 and 333-236042) on Form S-8, the registration statement (No. 333-214088) on Form S-3, and the registration statement (No. 333-220127) on Form S-3 ASR of Global Blood Therapeutics, Inc. and subsidiary of our report dated February 26, 2020, with respect to the consolidated balance sheets of Global Blood Therapeutics, Inc. and subsidiary as of December 31, 2019 and 2018, the related consolidated statements of operations and comprehensive loss, stockholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2019, and the related notes, and the effectiveness of internal control over financial reporting as of December 31, 2019, which report appears in the December 31, 2019 annual report on Form 10-K of Global Blood Therapeutics, Inc. and subsidiary.
Our report refers to a change in the method of accounting for leases as of January 1, 2019 due to the adoption of FASB Accounting Standards Update 2016-02, Leases (Topic 842).
/s/ KPMG LLP
San Francisco, California
February 26, 2020